Shammas Nicolas W, Mangalmurti Sarang, Bernardo Nelson L, Mehrle Anderson, Adams George, Bertolet Barry, Stavroulakis Konstantinos, Soukas Peter A
Midwest Cardiovascular Research Foundation, Davenport, IA, USA.
Main Line Hospitals, Bryn Mawr, PA, USA.
J Endovasc Ther. 2024 Jun 15:15266028241255622. doi: 10.1177/15266028241255622.
Surgical endarterectomy is currently considered the front-line therapy for the treatment of calcified lesions in the common femoral artery (CFA). Endovascular interventions have evolved, and their use is increasing in frequency. Intravascular lithotripsy (IVL) has shown promising safety and effectiveness in calcified CFA lesions in a small pilot study, but "real-world" evidence from a larger cohort is lacking.
The Disrupt PAD III Observational Study (NCT02923193) was a prospective, multicenter registry designed to assess the acute safety and effectiveness of IVL treatment for calcified peripheral arterial disease. Any concomitant treatment with other calcium-modifying technologies as well as definitive treatment strategies was at the discretion of the operators. Patients with CFA lesions were evaluated for acute angiographic safety and effectiveness outcomes following IVL treatment as determined by an independent angiographic core lab.
Common femoral artery treatment was indicated in 177 patients (n=163 could be analyzed based on core-laboratory data) enrolled at 23 sites. Characteristics for 164 treated lesions included moderate-severe calcification 95.1%, diameter stenosis 74.8±17.7%, and lesion length 53.6±53.1 mm. Concomitant calcium-modifying therapy was used in 32.3% of lesions. Final therapy included drug-coated balloons in 68.9% and stenting in 16.5% of lesions. Post-IVL and final residual stenoses were 29.2±16.5%and 23.6±11.5%, respectively. No vascular complications (flow-limiting dissections, perforations, embolization, slow or no reflow, or abrupt closure) were present at the end of the procedure by core-laboratory assessment, with 1 (0.8%) flow-limiting dissection initially occurring immediately following IVL treatment.
This study represents the largest real-world experience of IVL treatment in heavily calcified CFA lesions. Intravascular lithotripsy treatment showed significant stenosis reduction and favorable periprocedural safety in this challenging patient population.
In this study we show that calcified common femoral artery disease can be safely and effectively treated with shockwave balloon angioplasty with high procedural success and low complication rates and in clinical practice can now be offered as an alternative to surgical treatment in those patients reluctant to or high risk for vascular surgery. This opens another option for clinicians to treat calcified common femoral artery disease without the risk of dissection, perforation or distal embolization that are associated with atherectomy. This study shows that shockwave lithoplasty offers an innovative plaque modification technology to tackle calcified disease in the common femoral artery.
目前,外科动脉内膜切除术被认为是治疗股总动脉(CFA)钙化病变的一线疗法。血管内介入治疗不断发展,其使用频率也在增加。在一项小型试点研究中,血管内碎石术(IVL)已在CFA钙化病变中显示出良好的安全性和有效性,但缺乏来自更大队列的“真实世界”证据。
Disrupt PAD III观察性研究(NCT02923193)是一项前瞻性、多中心注册研究,旨在评估IVL治疗钙化外周动脉疾病的急性安全性和有效性。是否采用其他钙修饰技术以及确定性治疗策略的任何联合治疗由操作者自行决定。对患有CFA病变的患者进行评估,以确定IVL治疗后由独立血管造影核心实验室判定的急性血管造影安全性和有效性结果。
23个研究地点纳入了177例患者(根据核心实验室数据可分析163例)进行股总动脉治疗。164处治疗病变的特征包括中重度钙化95.1%、直径狭窄74.8±17.7%、病变长度53.6±53.1mm。32.3%的病变采用了联合钙修饰治疗。最终治疗包括68.9%的病变使用药物涂层球囊和16.5%的病变使用支架植入。IVL术后和最终残余狭窄分别为29.2±16.5%和23.6±11.5%。根据核心实验室评估,手术结束时未出现血管并发症(限流性夹层、穿孔、栓塞、缓慢或无复流或急性闭塞),1例(0.8%)限流性夹层最初在IVL治疗后立即出现。
本研究代表了IVL治疗严重钙化CFA病变的最大规模真实世界经验。在这一具有挑战性的患者群体中,血管内碎石术治疗显示出显著的狭窄减轻和良好的围手术期安全性。
在本研究中,我们表明钙化性股总动脉疾病可以通过冲击波球囊血管成形术安全有效地治疗,手术成功率高,并发症发生率低,在临床实践中,对于那些不愿意接受血管手术或血管手术风险高的患者,现在可以作为手术治疗的替代方案。这为临床医生治疗钙化性股总动脉疾病开辟了另一种选择,避免了与旋切术相关的夹层、穿孔或远端栓塞风险。本研究表明,冲击波碎石成形术为解决股总动脉钙化疾病提供了一种创新的斑块修饰技术。